These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25677660)

  • 1. Discovery of novel antagonists of glycoprotein IIb/IIIa-mediated platelet aggregation through virtual screening.
    Wang Y; Zhao Y; Sun R; Kong W; Wang B; Yang G; Li Y
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1249-53. PubMed ID: 25677660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based virtual screening of small-molecule antagonists of platelet integrin αIIbβ3 that do not prime the receptor to bind ligand.
    Negri A; Li J; Naini S; Coller BS; Filizola M
    J Comput Aided Mol Des; 2012 Sep; 26(9):1005-15. PubMed ID: 22893377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the research of GPIIb/IIIa antagonists.
    Xie Z; Cao C; Feng S; Huang J; Li Z
    Future Med Chem; 2015; 7(9):1149-71. PubMed ID: 26132524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of PFA-100 closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro.
    Stegnar M; Bozic M; Dolenc MS; Anderluh PS; Kikelj D
    Clin Chem Lab Med; 2007; 45(11):1542-8. PubMed ID: 17970708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb/IIIa inhibits platelet aggregation.
    Li YX; Sun Q; Zhang H; Ren ST; Liao YR; Wang Y; Shen XL; Wang B
    Thromb Res; 2012 May; 129(5):e217-22. PubMed ID: 22445430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY; Wu YC; Wu CC
    Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.